CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia

Authors

Jeffrey E Lancet, H. Lee Moffitt Cancer Center and Research Institute
Geoffrey L Uy, Washington University School of Medicine in St. Louis
et al

Journal

Journal of Clinical Oncology

Publication Date

9-10-2018

Volume

36

Issue

26

First Page

2684

Last Page

2692

Document Type

Open Access Publication

DOI

10.1200/JCO.2017.77.6112

Rights and Permissions

Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna Hogge, Scott R. Solomon, Richard M. Stone, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel H. Ryan, Antje Hoering, Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, and Bruno C. Medeiros (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 36(26):2684-2692. DOI: 10.1200/JCO.2017.77.6112

Recommended Citation

Lancet, Jeffrey E; Uy, Geoffrey L; and et al, "CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia." Journal of Clinical Oncology. 36, 26. 2684 - 2692. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8450